摘要
进展期胃癌的预后仍然较差。目前资料明确提示,如果没有对疾病生物学特征的深刻理解,新发展的药物几乎不可能成功。随着对肿瘤相关分子信号通路的深入研究,以关键分子通路中的某些关键分子为靶点的生物制剂得到开发与应用。抗人类表皮生长因子(HER)2药物曲妥珠单抗在进展期胃癌患者中应用的Ⅲ期临床试验中取得了阳性结果,证实了这种方法的有效性。目前有不少靶向HER2药物治疗胃癌的临床试验已经结束或正在进行。
The prognosis of advanced gastric cancer is still poor.If there′s no deep understanding of the disease′s biological characteristics,the present datas hint clearly that it′s nearly impossible to develop new drugs.Along with the deep-going researchs on tumor-related molecular signaling pathways,biological agents targeting key molecules in key signaling pathways are developed and applied.The use of human epidermal growth factor receptor（HER）2-targeted drug trastuzumab has gained positive result in Phase Ⅲ clinical trials in treating gastric cancer,which proved the effect of the method.Currently several clinical trials of HER2-targeted drugs treating gastric cancer are either finished or in progress.
出处
《医学综述》
2012年第2期198-200,共3页
Medical Recapitulate
关键词
人类表皮生长因子2
胃癌
曲妥珠单抗
拉帕替尼
Human epidermal growth factor receptor-2
Gastric cancer
Trastuzumab
Lapatinib
